Seqirus

Seqirus was established on 31 July 2015, following CSL's acquisition of the Novartis influenza vaccines business and was subsequently integrated with bioCSL. Seqirus is the world's second largest influenza vaccine company and a major partner in the prevention and control of influenza globally. It is a reliable supplier of influenza vaccine for Northern and Southern Hemisphere markets and a transcontinental partner in pandemic preparedness and response.

Seqirus operates state-of-the-art production facilities in the US, the UK and Australia, and manufactures influenza vaccines using both egg-based and cell-based technologies. It has leading R&D capabilities, a broad portfolio of differentiated products and commercial operations in more than 20 countries.

In Australia and the Asia Pacific region, Seqirus is a leading provider of in-licensed vaccines and specialty pharmaceuticals. It also manufactures and markets diagnostics for immunohematology laboratories and is the sole supplier of a unique range of products made in the national interest for the Australian Government, including antivenoms and Q fever vaccine.

Seqirus has established a corporate office in Maidenhead, United Kingdom. Visit Seqirus.com




bioCSL



Seqirus Australia

Our manufacturing facility in Melbourne, Australia, has been producing flu vaccine for nearly five decades. In Australia Seqirus also continues a long legacy of manufacture of Products of National Significance and markets and distributes a range of vaccines and specialty pharmaceuticals in both Australia and New Zealand. 

For information about the vaccines, anti-venoms, in-licensed pharmaceuticals and immunohaematology products (diagnostic reagents) that Seqirus distributes in Australia please visit the Seqirus Australia website.

If you are interested in new partnerships regarding in-licensed pharmaceuticals, please visit the Seqirus Australia website for more information.

CSL direct provides a convenient ordering portal for Seqirus products and Vaccines, visit the CSL Direct website. If you would like more information about CSL direct, please contact CSL customer service on 1800 008 275.



Seqirus New Zealand

For information about prescription medicines and vaccines that Seqirus distributes in New Zealand visit the Seqirus New Zealand website.



Seqirus United States

Seqirus has a state-of-the-art vaccine producing facility at our Holly Springs site in the US. The use of a novel cell culture-based process is a alternative to traditional egg-based influenza vaccine production, and gives Seqirus vital additional capacity, particularly in the event of a pandemic. 

For information about influenza vaccines that Seqirus distributes in the USA visit the Seqirus United States website.


Seqirus United Kingdom

Seqirus has established a corporate office in Maidenhead, United Kingdom. Visit Seqirus.com

Seqirus Liverpool in the UK, a Centre of Excellence for egg-based influenza vaccine manufacturing. It is one of the biggest biotechnology sites in Europe and the only injectable influenza vaccine manufacturer in the UK. It also produces the only licensed adjuvanted seasonal influenza vaccine.  

 




© 2017 CSL Limited